A leading lawmaker is intensifying his scrutiny of the financial ties between opioid makers, advocacy groups, and government panels that provide advice on the controversial and lucrative business of managing patient pain.

In a letter to the Department of Health and Human Services, Sen. Ron Wyden (D-Ore.) asked the agency to review various conflicts of interest among some members of the Pain Management Best Practices Inter-Agency Task Force, which was created two years ago to make recommendations for combating chronic and acute pain. Those directives may affect Medicare and Medicaid reimbursements.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy